Key result
ESKD in aortic stenosis is linked to a 100% major event rate vs 63% in controls.
Why the study?
Patients with end-stage kidney disease (CKD 5D) have an increased rate of aortic stenosis progression, but the impact on major event-free survival was unknown.
Does end-stage kidney disease accelerate the progression to aortic valve replacement or death in patients with aortic stenosis compared to controls?
Comparison
CKD 5D patients vs controls matched by aortic valve area
Design
Prospective cohort study
Follow-up
Until all CKD 5D subjects had undergone AVR or died
Authors
Loading...
CKD 5D patients with AS reached AVR or death sooner than controls; extends progression data but leaves open whether earlier AVR improves outcomes.
Cohort (n=54)
Does end-stage kidney disease accelerate the progression to aortic valve replacement or death in patients with aortic stenosis compared to controls?
Absolute Event Rate: 100% vs 63%
p-value: p=0.001
Patients with end-stage kidney disease and aortic stenosis have significantly shorter major event-free survival compared to controls, suggesting a potential need for early aortic valve replacement.
Zentner et al. (2010) conducted a cohort in Aortic stenosis in end-stage kidney disease (n=54). End-stage kidney disease (CKD 5D) vs. Controls without end-stage kidney disease was evaluated on Major event-free survival (AVR or death) (p=0.001). End-stage kidney disease in patients with aortic stenosis was associated with worse major event-free survival (AVR or death) compared to matched controls (100% vs 63%; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: